From Financialpost · · 50s
Psyence BioMed Partners with Benuvia for U.S. Ibogaine Manufacturing
Psyence BioMed and Benuvia launch U.S. pharmaceutical-grade ibogaine production under DEA-registered facility.
In brief
Psyence BioMed and Benuvia launch U.S. pharmaceutical-grade ibogaine production under DEA-registered facility. Psyence BioMed's Texas subsidiary partners with Benuvia to manufacture ibogaine in the U.S. using DEA-registered facilities. Originally reported by Financialpost.
Partnership Announced
Psyence BioMed's Texas subsidiary TIRC entered manufacturing partnership with Benuvia Operations for u.s. pharmaceutical-grade ibogaine production.
Benuvia's Facility
Benuvia operates an 83,000-square-foot dea-registered facility in round rock texas with controlled-substance manufacturing capabilities.
Manufacturing Plan
Partnership connects tirc's exclusive u.s. ibogaine supply with benuvia's u.s. manufacturing infrastructure for pharmaceutical-grade production.
Regulatory Pathway
Benuvia holds approximately half of u.s. ibogaine production quota and is advancing dea import permits for planned u.s. manufacturing.
CEO Statement
Jody Aufrichtig said benuvia brings dea-registered u.s. facility with quota and systems to create end-to-end ibogaine production pathway.
Here's the gist
Psyence BioMed's Texas subsidiary partners with Benuvia to manufacture ibogaine in the U.S. using DEA-registered facilities.
